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Abstract
Background: Mild cognitive impairment (MCI) is set to become a major health problem with the exponential ageing of the
world’s population. The association between MCI and autonomic dysfunction, supported by indirect evidence and rich with
clinical implications in terms of progression to dementia and increased risk of mortality and falls, has never been specifically
demonstrated.
Aim: To conduct a comprehensive assessment of autonomic function in subjects with MCI by means of power spectral
analysis (PSA) of heart rate variability (HRV) at rest and during provocative manoeuvres.
Methods: This cross-sectional study involved 80 older outpatients (aged $65) consecutively referred to a geriatric unit and
diagnosed with MCI or normal cognition (controls) based on neuropsychological testing. PSA was performed on 5-minute
electrocardiographic recordings under three conditions—supine rest with free breathing (baseline), supine rest with paced
breathing at 12 breaths/minute (parasympathetic stimulation), and active standing (orthosympathetic stimulation)—with
particular focus on the changes from baseline to stimulation of indices of sympathovagal balance: normalized low
frequency (LFn) and high frequency (HFn) powers and the LF/HF ratio. Blood pressure (BP) was measured at baseline and
during standing. Given its exploratory nature in a clinical population the study included subjects on medications with a
potential to affect HRV.
Results: There were no significant differences in HRV indices between the two groups at baseline. MCI subjects exhibited
smaller physiological changes in all three HRV indices during active standing, consistently with a dysfunction of the
orthosympathetic system. Systolic BP after 10 minutes of standing was lower in MCI subjects, suggesting dysautonomia-
related orthostatic BP dysregulation.
Conclusions: Our study is novel in providing evidence of autonomic dysfunction in MCI. This is associated with orthostatic
BP dysregulation and the ongoing follow-up of the study population will determine its prognostic relevance as a predictor
of adverse health outcomes.
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Introduction
Mild cognitive impairment (MCI) is a clinical entity that lies
along the continuum from cognitively normal ageing to dementia
[1–3]. It is characterized by a slight cognitive impairment, greater
than expected for an individual’s age and education but not severe
enough to warrant a diagnosis of dementia, that does not
substantially interfere with functional independence, although
there may be some minimal deficits in the more complex
instrumental activities of daily living [1–3]. It stands out as a
major public health problem because it is increasingly recognized
to be the prodromal stage of dementia, with an annual conversion
rate ranging from 5 to 15% across different studies [3] and it
affects a consistent portion of the population. In fact the
prevalence of MCI among older adults aged 65 and over has
been reported to be between 11 and 17%, i.e. from two to four
times that of dementia [4,5], and the absolute number of subjects
with MCI is bound to rise exponentially with the rapid ageing of
the population. Indeed in Italy, the third oldest country in the
world with its 20% prevalence of elderly [6], the number of older
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e96656
adults is estimated to soar from just above 12 million in 2010 to
just above 21 million in 2043 [7].
Heart rate variability (HRV) is the physiological phenomenon
by which the heart rate (HR), far from displaying metronome-like
regularity, changes from beat to beat, producing fluctuations in the
time intervals between consecutive R waves (RR intervals) on an
electrocardiographic (ECG) recording. HRV is considered to
reflect the influence of the two limbs of the autonomic nervous
system (ANS) –orthosympathetic and parasympathetic- on sinus
node activity [8–10]. The analysis of HRV, available in most
commercial Holter devices, thus provides a simple, non-invasive
and reliable method for the assessment of autonomic function and
as such has been extensively employed in clinical research [11].
In the literature there are two main lines of indirect evidence
that suggest an association between MCI and autonomic
dysfunction. First, MCI is considered a condition of predementia
and a number of studies have demonstrated an impaired
autonomic function in dementia, whether by clinical autonomic
tests [12–16] or HRV analysis [17–21]. Also, a recent study has
shown that, within a group of patients with Alzheimer’s disease
(AD), there was a positive correlation between cognitive status and
parasympathetic HRV indices [22]. Second, MCI is characterized
by a slight cognitive impairment and several studies, although with
some exception [23], have revealed a significant association
between the performance on cognitive tests and HRV-derived
autonomic function across different age groups and conditions. In
fact a relationship between cognitive functioning and HRV has
been found in infants [24], children [25], young [26–29], middle-
aged [29,30] and older adults [31,32] as well as in subjects
suffering from anxiety [33–35]. To the best of our knowledge there
are only two studies that have addressed the issue of autonomic
function in MCI subjects relative to cognitively normal controls.
The first [36] is a transcranial Doppler study, primarily conceived
to investigate cerebrovascular reactivity to vasodilator/vasocon-
strictor stimuli, that only collaterally reports a deficient response of
the HR to hypercapnia in MCI patients. The second is a study by
Zulli et al. [19] who evaluate autonomic function by means of
HRV analysis, but fail to highlight differences in HRV indices
between MCI and controls, possibly due to the lack of fully-
controlled conditions (24-hour out-of-hospital ECG with power
spectral analysis (PSA) performed on a 1-hour period during which
the patient was instructed to remain supine and awake) as well as
of provocative tests that may unmask a more a subtle dysauto-
nomia by challenging the ANS [37].
The potential clinical significance of autonomic dysfunction in
MCI is manifold. Reduced HRV has been found to be associated
with increased all-cause mortality in the general elderly population
[11] and in MCI subjects the relative risk of mortality, compared
to controls, has indeed been reported to vary from 1.7 to 2.3
[38,39]. Autonomic dysfunction can lead to blood pressure (BP)
dysregulation [40] which can in turn prompt syncope and falls via
hypotensive episodes [41] and potentially also through white
matter lesions (WMLs) [42,43] that impair balance and gait [44].
In fact the autonomic symptom score was documented to be a
predictor of falls in dementia [45]. Falls are an important cause of
morbidity, mortality and institutionalization in elderly people [46],
and there is emerging data on MCI as a risk factor for falls [47,48].
Moreover, particularly relevant to MCI is the hypothesis that BP
dysregulation may result in cerebral hypoperfusion and brain
damage that contribute to the progression of cognitive decline
towards overt dementia. Support to such hypothesis comes from
different works in the literature. There is a wealth of studies, in
elderly subjects spanning a wide range of cognitive states, that
report the association of BP dysregulation –in terms of absolute BP
values, circadian BP pattern, orthostatic BP changes and BP
variability (BPV) – with both cognitive impairment [19,49–52] and
WMLs/silent cerebral infarcts [42,43]. Also, in older adults there
is consistent evidence in favour of the role of silent cerebrovascular
damage in predicting the likelihood and rate of subsequent
cognitive decline and the risk of conversion to dementia [53], and
within a group of MCI subjects it has been shown that reduced
HRV indices correlate with increasing WML severity [54].
Lastly, autonomic dysfunction can be affected by a broad
spectrum of medications - not only cardioactive ones [11]- and this
is a matter of general concern in elderly subjects in whom
polypharmacy is common [55] as well as a question of specific
interest in MCI patients to whom cholinesterase inhibitors may be
prescribed on the basis of their risk of progression [3].
The aim of this study was to evaluate autonomic function in
subjects with MCI, compared with cognitively normal controls, by
means of PSA of HRV applied to a controlled experimental
protocol including two provocative tests: active standing (ortho-




In this cross-sectional case-control study we considered for
inclusion 475 community-dwelling older subjects (aged $65) who
consecutively attended a first geriatric visit at the Geriatric
Outpatient Unit of the Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico in Milan, Italy, from January to December
2012, to which they had been referred by their general
practitioners (GPs) for a broad spectrum of age-related health
problems. 80 subjects with a known diagnosis of dementia were
excluded while the remaining 395 were assessed for eligibility by
applying a number of exclusion criteria (see later). We thus
identified 117 eligible subjects who were all invited to undergo an
on-site neuropsychological evaluation. Of the 113 subjects who
agreed to neuropsychological testing, 23 were diagnosed with
dementia and were excluded, leaving 90 subjects with a diagnosis
of MCI or normal cognition (NC). Of these, 5 declined
participation so that the study eventually enrolled 85 subjects
(n = 41 MCI: cases, n = 44 NC: controls), all of them recruited
from the same population (Figure 1). Since all eligible subjects
were invited to undergo neuropsychological testing independently
of cognitive functioning there was no selection of the sample in
such sense.
Exclusion criteria were: 1) non-sinus rhythm (atrial fibrillation
and other arrhythmias, paced rhythms) since HRV analysis is, by
definition, performed on sinus beats; 2) clinical conditions with an
established and significant effect on HRV: history of heart disease
(coronary artery disease (CAD), heart failure (HF)) [8], diabetes
mellitus [8], neurological and psychiatric diseases (Parkinson’s
disease, stroke, major depression) [8,56,57], and severe diseases
(respiratory, renal, hepatic, autoimmune and neoplastic) [58]; 3)
use of several cardioactive medications: beta-blockers, alpha-
blockers, centrally-acting calcium-channel blockers (CCBs), class I
and III antiarrhytmic drugs, digoxin; 4) use of several psychotropic
medications: tricyclic antidepressants, selective serotonin-nor-
adrenaline reuptake inhibitors (SNRIs), atypical antidepressants,
antipsychotics and cholinesterase inhibitors.
Among cardioactive medications we allowed diuretics, periph-
erally-acting CCBs and ACE-inhibitors (ACE-Is)/angiotensin II
receptor blockers (ARBs) while among psychotropic medications
selective serotonin reuptake inhibitors (SSRIs) and benzodiaze-
pines were permitted. In particular, we recorded as benzodiaze-
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pine users subjects who were regular users, while intermittent users
were asked to refrain from taking benzodiazepines in the two days
prior to the neuropsychological and autonomic testing (48 hours
corresponding to the maximum overall duration of action of long-
half-life benzodiazepine diazepam) [59]. As far as the choice of
medication exclusion/inclusion criteria is concerned please see the
Discussion for details.
The diagnosis of MCI was made according to current consensus
criteria [1,2,60]: objective cognitive impairment on neuropsycho-
logical testing, essentially preserved daily functioning and absence
of dementia. The neuropsychological evaluation was based on a
comprehensive battery of neuropsychological tests investigating
different cognitive domains: 1) attention: digit cancellation [61]
and bell [62] tests; 2) memory: prose recall [61], Rey-Osterrieth
complex figure-delayed recall [63], digit span forward [64]; 3)
executive functions: digit span backward [65], trail-making tests A
and B [66], Weigl’s colour-form sorting test [61], cognitive
estimates [67], Raven’s coloured progressive matrices [68], letter
fluency [69]; 4) language: category fluency [61], picture naming
[70], token test [61]; 5) visuospatial skills: Rey-Osterrieth complex
figure-copy [63], copy of geometric figures [61]; 6) ideomotor
praxis: De renzi’s test [71]. MCI was diagnosed in individuals who
were impaired in at least one cognitive domain. Impairment in a
cognitive domain was defined as an abnormal performance in at
least one test within that domain. Subjects were therefore classified
as MCI if they showed an abnormal performance in at least one
test of the neuropsychological battery. A test performance was
considered abnormal when it fell below the 10 th percentile of
published normative data for the Italian population [61–71], i.e.
when it corresponded to the ‘‘worst’’ 10% of the distribution of
scores obtained by available reference samples of cognitively
normal subjects, age-, gender- and education adjusted where
appropriate (please refer to Table S1 for the test scores and cut-
offs). The 10 th percentile threshold was selected, in accordance
with several authors (e.g [72–74]), because we believe that, relative
to the other options of 1.5 and 1 standard deviations below norms
(i.e. 7 th and 16 th percentile), also commonly accepted [75], it
provides a more appropriate balance between the risk of under-
and over-diagnosing MCI.
The 85 subjects taking part in the study underwent a clinical
and autonomic assessment within one month from the neuropsy-
chological evaluation.
Clinical assessment
All subjects received a detailed clinical assessment to collect
information on those characteristics that have been shown to affect
HRV, either directly or via subclinical CAD [58,76] and/or are
relevant to a standard geriatric evaluation.
Sociodemographics (age, gender, education), lifestyle habits
(smoking, coffee and alcohol consumption, physical activity),
history of hypertension, medication history, family history of
premature CAD [77] and routine blood tests (glucose, lipid panel)
were recorded. Body mass index (BMI) was calculated as weight
(kg)/height (m2); alcohol consumption was expressed as alcohol
units/day (1 unit = 10 g alcohol) based on the average alcohol
content by volume of the drinks consumed [78]; physical activity
was quantified in MET (metabolic equivalent)-hours/week (1
MET = 1 kcalNkg21Nh21) by means of a semistructured question-
naire in which MET values were assigned to different activities
[79].
Target organ damage, in terms of left ventricular hypertrophy
and carotid atherosclerosis, was also evaluated. Patients who did
not have a recent (within the past year) echocardiogram or carotid
Doppler scan underwent instrumental examination.
Functional status was assessed by means of the scales for the
Basic Activities of Daily Living (BADL) [80] and for the
Instrumental Activities of Daily Living (IADL) [81]; comorbidity
by means of the Cumulative Illness Rating Scale (CIRS) severity
(CIRS-s) and morbidity (CIRS-m) scores [82]; anxiety symptoms
by means of the State Trait Personality Inventory-Trait anxiety
subscale (STPI-T) [83]; depressive symptoms by means of the
Geriatric Depression Scale short (15-item) version (GDS-s) [84].
The Mini Mental State Examination (MMSE) [85], corrected for
age and education, was used to provide an estimate of global
cognitive functioning, but, due to its recognized poor sensitivity to
early cognitive impairment [3], it was not included in the battery
of diagnostic tests for MCI.
Autonomic assessment
The autonomic assessment was carried out in a quiet room, with
dimmed lighting and a comfortable temperature (22-24uC),
Figure 1. Flow diagram of the study population. NPS: neuropsy-
chological; NC: normal cognition (controls); MCI: mild cognitive
impairment; HRV: heart rate variability.
doi:10.1371/journal.pone.0096656.g001
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between 8:30 and 11:30 a.m. in order to minimize the effect of
circadian changes in HRV [86]. Patients were instructed to
consume a light breakfast and refrain from caffeinated beverages,
alcohol, smoking and vigorous physical activity in the 12 hours
prior to testing. After a standard 12-lead ECG, three-channel
ECG recordings for HRV analysis were obtained by means of a
digital Holter recorder (Spider View, Sorin Group Company).
The protocol was composed of three stages (Figure 2): 1) supine
rest with free breathing (baseline): 15 minutes during which the
subjects were asked to remain awake, silent and still, breathing
spontaneously. To allow for stabilization only the last 5 minutes
were analysed; 2) active standing (orthosympathetic stimulation)
[8–10]: 10 minutes during which the subjects were asked to remain
still and silent, after standing upright in as smooth a motion as
possible. We chose to analyse the last 5 minutes since 5 minutes is
the time believed to be necessary for adjustment of autonomic
function to posture [87] and lies at the upper range of the
stabilization period adopted by most HRV studies involving
orthostatic testing (e.g. [21,22,88]). We opted for an active rather
than passive standing test because the former is more easily
implemented in routine geriatric clinical practice and there is
evidence that the two manoeuvres are comparable in terms of
changes in autonomic balance [89]; 3) supine paced breathing at
12 breaths/min (0.2 Hz) (parasympathetic stimulation) [10]: 15
minutes during which the subjects breathed, as regularly as
possible and with a ‘‘comfortable’’ tidal volume, according to an
electronic metronome set at 24 acoustic signals per minute (2.5 s
inspiration, 2.5 s expiration). Given the nature of our study
population, this stage was made as simple as possible: the first 10
minutes were devoted to familiarization with the breathing
protocol, without recording, and throughout the subjects were
not asked to directly synchronize their breathing rhythm with the
metronome but to follow voice indications from the experimenters.
Within the 12–20 breaths/min respiratory rate range, associated
with an enhancement of parasympathetic modulation [10], we
chose the lowest respiratory rate because in a preliminary
investigation we found it was the easiest for our subjects to
maintain.
BP and HR were recorded at the end of the baseline period,
after 1, 3, 5 and 10 minutes of active standing and at the end of the
paced breathing, using a validated digital spyghmomanometer
over the brachial artery (OMRON M6). Orthostatic hypotension
(OH) was defined as a drop in systolic BP (SBP)$20 mm Hg and/
or a drop in diastolic BP (DBP) $10 mm Hg [90] relative to
baseline in at least one orthostatic recording; we extended the
recording period beyond 3 minutes since milder autonomic
dysfunction has been associated with delayed OH [91].
Since respiratory rate is a potent determinant of HRV [92], the
spontaneous respiratory rate was visually assessed during the
baseline and active standing periods. Subjects with a respiratory
rate #9 breaths/min (# 0.15 Hz) were excluded due to the
overlapping of the low- and high-frequency bands which precludes
proper interpretation of PSA [93]. Based on the fact that
emotional stress can have a confounding effect on HRV [8] and
can be influenced by cognitive status, at the end of the active
standing and paced breathing periods subjects were asked to rate
their level of stress on a visual analogue scale (VAS) from 0 (no
stress) to 100 (maximum stress).
HRV analysis
HRV analysis was performed in the frequency domain (PSA) on
each of three 5-minute ECG recordings (baseline, active standing,
paced breathing), in accordance with the guidelines of the Task
Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology [8]. We used
commercially available software (Synescope version 3.10, Sorin
Group Company) which carries out PSA by means of the Fast
Fourier Transform (FFT), after linear interpolation/resampling at
4 Hz of the discrete event series (to obtain a regularly time-
sampled signal) and filtering with a Hanning window (to attenuate
leakage effects). Although the software automatically detect non-
sinus beats, the recordings were always manually overread by
experienced investigators – blinded to the subjects’ cognitive
status- in order to ensure correct QRS complex classification and
rhythm identification. The software corrects for ectopics by
eliminating one RR interval before and after each non-sinus beat
and replacing them with RR intervals computed by linear
interpolation based on the surrounding normal beats [8]. This
method is more appropriate than simple deletion (i.e. removal of
the two non-normal RR intervals without replacement) because
the latter leads to loss of data which may be critical in the case of
short-term recordings and is also associated with a phase shift to
which frequency-domain measures are particularly sensitive [94].
Since there is no clear indication in the literature as to the amount
of ectopic beats that it is acceptable to remove or remove and
interpolate [95,96], with the exclusion threshold ranging from 1%
[97] to 20% [98] of the total number of beats in different studies,
we chose the most restrictive criterion. This is in line with the
suggestion by Kamath et al. [95] that in a short-term study (less
than 5 minutes) there should be no more than two to three ectopic
beats. Thus, recordings with excessive supraventricular or
ventricular ectopy- i.e. ectopic beats .1% of total beats - were
excluded from analysis, as were those with other arrhythmias.
The resulting spectral indices were: 1) very low frequency power
(VLF, #0.04 Hz), low frequency power (LF, 0.04-0.15 Hz), high
frequency power (HF, 0.15–0.4 Hz) and total power (TP, #
0.4 Hz) which are expressed in absolute units (ms2) and are
computed by integrating the area under the power spectrum
within the specified frequency range; 2) normalized LF (LFn) and
high frequency (HFn) power which are expressed in normalized
Figure 2. Timeline of the three stages of the experimental protocol. HRV: heart rate variability.
doi:10.1371/journal.pone.0096656.g002
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units (n.u.) and correspond to the absolute power divided by TP
minus VLF and multiplied by 100; and 3) the LF/HF ratio which
is the ratio of LF to HF. Two methodological issued deserve
mention herein. First, we chose to mainly focus on those indices
that better reflect the reciprocal interaction between the two
branches of the ANS: LFn (an index of orthosympathetic
modulation), HFn (an index of parasympathetic modulation) and
the LF/HF ratio (an index of sympathovagal balance) [9].
TP, LF and HF were considered only for the sake of comparison
with other studies because they suffer from some limitations. TP is
an index of overall autonomic modulation and as such does not
allow to separately assess the behaviour of the ortho- and
parasympathetic limbs of the ANS. LF and HF are influenced
by changes in TP in the same direction, which prevents
appreciation of the fractional distribution of the energy (e.g. both
decrease, albeit to different extents, during tilt) [8,9]. Indeed the
interpretation of the LF component is controversial: according to
some investigators it is an index of predominant orthosympathetic
modulation while others regard it as index of mixed ortho- and
parasympathetic modulation [8]. Although HF is an index of
predominant parasympathetic modulation [8,9] there is evidence
in the literature that HFn provides more accurate information on
the state (activation/withdrawal) of the parasympathetic nervous
system. In fact it has been shown that HFn, relative to HF, is
characterized by a stronger (negative) correlation with the angle of
tilt during graded orthostatic tilt [99] and with muscle sympathetic
nerve activity quantified by microneurography during pharmaco-
logically-induced BP changes [100]. VLF, whose physiological
significance is still uncertain and probably related to the renin-
angiotensin-aldosterone system, thermoregulation and vasomotor
activity [9], was not taken into account.
Second, LFn, HFn and the LF/HF ratio were considered in
each of the three stages of the protocol (baseline, active standing
and paced breathing) but particular attention was devoted to their
changes from baseline to stimulation : DLFn, DHFn, DLF/HF.
These latter indices represent the response to the manoeuvre and
are especially sensitive measures of autonomic modulation,
extensively used in HRV studies (e.g. [88,101–105]) because they
explore the dynamic range of the ANS [37,88].
Statistical analysis
Data are reported as mean (standard deviation) for continuous
variables and number (percentage) for categorical variables. The
comparison between the two groups was carried out by means of:
1) the chi-squared test or Fisher’s exact test for categorical
variables; and 2) the independent samples Student’s t-test or the
Mann-Whitney U-test for continuous variables with a normal and
non-normal distribution respectively; the normality of the data was
assessed by using the Shapiro-Wilk test. In particular, HRV
indices that were not normally distributed (HFn and LF/HF) were
normalized by logarithmic transformation to base 10 (lg) in order
to apply parametric statistics. Inflation of type I error due to
multiple testing was controlled for by means of the Benjamini-
Hochberg procedure [106] with the False Discovery Rate (FDR)
set at the conventional level for alpha (q = 5%). This was preferred
to the Bonferroni correction because the latter is known to be
overly conservative in the case of highly correlated variables, like
ours, leading to an undue loss in statistical power (i.e. an increase
in false negatives) which would be inappropriate also given the
exploratory nature of the study [107]. Multiple linear regression
was used to adjust for potential confounders, which were chosen
among the variables that were different between the two groups
(i.e. CIRS and VAS-stress scores) and/or are particularly relevant
to HRV or BP (i.e. medication use and HR). Specifically, the
standing (and D standing) HRV indices were corrected for the
CIRS-m and the standing VAS-stress scores, for medication use
(ACE-Is/ARBs, diuretics, peripherally-acting CCBs, SSRIs, ben-
zodiazepines) and for the average standing HR. Similarly, the
paced breathing HRV indices were corrected for the CIRS-m and
the paced breathing VAS-stress scores, for medication use and for
the HR at the end of paced breathing. The SBP after 10 minutes
of standing was corrected for the CIRS-m and VAS-stress standing
scores as well as for antihypertensive medication use (ACE-Is/
ARBs, diuretics, peripherally-acting CCBs). As far as comorbidity
was concerned only the CIRS-m score was entered in the analyses
to avoid redundancy (CIRS-m and CIRS-s being strongly
correlated, Spearman’s rho = 0.822, p,0.001). All variables
satisfied the assumptions of normality (non-significance of the
Shapiro-Wilk test), homoscedasticity (non-significance of Levene’s
test) and no-multicollinearity (variance inflation factor, VIF ,5)
[108]. A p value #0.05 was considered statistically significant.
Analyses were performed by means of the statistical package SPSS
version 19.0 for Windows (SPSS Inc., Chicago, IL).
Ethics Statement
This study was conducted in accordance with the Declaration of
Helsinki and was approved by the ethics committee of the
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in
Milan, Italy. All participants gave written informed consent to
participation in the study.
Results
Of the 85 participants, 5 were excluded during the experimental
session (n = 1 baseline respiratory rate , 9 breaths/min, n = 1
postural vasovagal reaction) or the HRV analysis (n = 1 paroxys-
mal supraventricular tachycardia, n = 2 excessive ectopic beats),
thus the study ultimately included 80 subjects, 40 with MCI and
40 with NC (control group) (Figure 1). It is important to note that,
during paced breathing, all subjects breathed at the target
respiratory rate of 12 breaths/min, as demonstrated by the centre
frequency of the HF peak (0.2 Hz) on PSA.
The 80 subjects included were not significantly different from
the 475 subjects considered for inclusion in terms of age (78.6 vs
78.5 years, p = 0.958), smoking habits (3.8% vs 4.6% smokers,
p = 1.000) and use of most allowed medications (ACE-Is/ARBs
48.8% vs 46.1%, p = 0.661; peripherally-acting CCBs 13.8% vs
19.6%, p = 0.216; SSRIs 27.5% vs 31.2%, p = 0.511; benzodiaz-
epines 18.8% vs 26.7%, p = 0.130). They were more frequently
females (75.0% vs 55.2%, p = 0.001), had a borderline higher
education (10.9 vs 10.0 years of schooling, p = 0.046), better
functional status (BADL score 5.5 vs 5.2, p = 0.006; IADL score
7.1 vs 5.3, p,0.001), better cognitive functioning (MMSE score
27.7 vs 25.5, p,0.001), lesser comorbidity (CIRS-s score 1.5 vs
1.6, p,0.001; CIRS-m score 2.1 vs 2.5, p = 0.019), consumed a
smaller number of medications (3.6 vs 5.3, p,0.001) and used less
diuretics (20.0% vs 32.8%, p = 0.022); the prevalence of hyper-
tension also tended to be lower in the study group, although the
difference just failed to attain statistical significance (56.3% vs
67.2%, p = 0.057).
Table 1 shows the baseline characteristics of the study subjects.
There were no significant differences between the two groups in
most factors, including cardiovascular (CV) risk ones, potentially
affecting autonomic function: sociodemographics, BMI, lifestyle
habits, routine blood tests, prevalence of hypertension and target
organ damage, family history of premature CAD, total number
and main classes of medications, anxiety and depressive symptoms,
BP values and respiratory rate (all p .0.1). In the MCI group,
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relative to controls, baseline HR was significantly higher
(p = 0.035) and CIRS-s and CIRS-m scores were significantly
lower (p = 0.029 and p = 0.006 respectively). As expected, MMSE
and IADL scores were significantly lower in the MCI group (p,
0.001 and p = 0.006 respectively). All subjects had normal blood
levels of vitamin B12, folate and thyroid hormones. None had
ischaemic ECG changes, pathological echocardiographic findings
(except for slight valvular disease which is common in older
people) or haemodinamically significant carotid stenosis. The
neuropsychological test results are reported in Table S1 and
indicate, as expected, a significantly poorer performance of MCI
subjects on tests across all cognitive domains (all p,0.04).
Table 2 shows the characteristics of the subjects during the
experimental session. After correction for multiple testing, the
MCI group exhibited a significantly lower SBP after 10 minutes of
standing (p = 0.047), a significantly higher HR at the end of paced
breathing (p = 0.018), a significantly lower standing VAS-stress
score (p = 0.041) and a marginally lower paced breathing VAS-
stress score (p = 0.055). It should be remarked that the respiratory
rate was comparable between the two groups, both in the standing
position (p = 0.201) and in the change from baseline to standing
(p = 0.526).
Table 3 displays the results of the PSA of HRV for the three
main indices considered in our study: LFn, HFn and LF/HF. TP,
LF and HF can be found in Table S2 and did not show statistically
significant differences between the two groups (independent
samples t-tests on log10 - transformed data, all p .0.1). Since
the HRV indices are presented untransformed for descriptive
purposes, please refer to Table S3 for the log 10-transformed
values.
After correction for multiple testing, there were a number of
significant differences in the HRV indices between the two groups,
which were confirmed after adjustment for potential confounders.
Notably, significant differences in the HRV indices between the
two groups were not found in baseline conditions, but only during
and in response to the provocative tests. During active standing, in
MCI subjects compared to controls, LFn and LF/HF were
significantly lower (p = 0.018 and p = 0.021 respectively) and HFn
was significantly higher (p = 0.049). In terms of the response to
active standing, in MCI subjects DLFn and DLF/HF were
significantly less positive (p = 0.041 and p = 0.004 respectively) and
DHFn was significantly less negative (p = 0.018) –i.e. the physio-
logical increase/decrease in HRV indices was significantly smaller.
During paced breathing, in MCI subjects relative to controls, LFn
and LF/HF were significantly higher (p = 0.041 and p = 0.049
respectively). These differences remained significant (standing:
LFn p = 0.009, HFn p = 0.018, LF/HF p = 0.006; D standing: LFn
p = 0.012, HFn p = 0.003, LF/HF p,0.001; paced breathing: LFn
p = 0.006, LF/HF p = 0.039) after adjustment for potential
confounders (CIRS-m and VAS-stress scores, medication use
and HR; please refer to the Statistical analysis for full details)
In terms of the response to paced breathing there were no
significant differences between MCI subjects and controls–i.e. the
physiological decrease in LFn and LF/HF and the physiological
increase in HFn were similar (p = 0.092, p = 0.154 and p = 0.422
respectively). Figure 3 illustrates that the SBP after 10 minutes of
standing was still significantly lower (p = 0.021) in the MCI group
following adjustment for potential confounders (CIRS-m and
VAS-stress standing scores as well as antihypertensive medication
use).
Discussion
To the best of our knowledge this is the first study, based on a
reliable and comprehensive assessment of autonomic function by
means of PSA of HRV in different conditions, to demonstrate
autonomic dysfunction in subjects with MCI compared to
cognitively normal controls. In particular, there are two main
findings. First, the autonomic dysfunction is not detectable in
baseline conditions but becomes manifest only during and in
response to the provocative tests and is consistent with an
asymmetric involvement of the two branches of the ANS, i.e. a
preferential impairment of the orthosympathetic component.
Second, it is associated with orthostatic BP dysregulation.
The lack of significant differences in HRV indices between the
two groups in baseline conditions is in line with the previous report
by Zulli et al. [19], but contrasts with the results of studies in
subjects with AD that show autonomic impairment already in the
resting supine state [18,19,21]. It is therefore reasonable to
suppose that MCI is characterized by a milder autonomic
dysfunction that is revealed only when the ANS is challenged.
The higher baseline HR observed in MCI subjects should
therefore not be interpreted as an expression of dysautonomia,
but is likely to be a spurious finding in the context of multiple
testing, also because no differences in resting HR relative to
controls have been found in MCI [19,36] or even AD subjects
[13,15,18,19,21].
As far as the provocative tests were concerned, in MCI subjects
during active standing LFn and LF/HF were lower and HFn was
higher, indicating a shift of sympathovagal balance towards
parasympathetic modulation, whereas during paced breathing
LFn and LF/HF were higher, indicating a shift of sympathovagal
balance towards orthosympathetic modulation (which translated
into an increased HR relative to controls at the end of this part of
the experimental session).
Most important, when focusing on the D HRV indices – which
represent the changes in HRV from baseline to stimulation and
enable the crucial assessment of the dynamic range of the ANS
[37,88]– the two branches of the ANS appear to be differentially
affected. In response to active standing the physiological increase
in LFn and LF/HF and the physiological decrease in HFn were
smaller in MCI subjects, reflecting a dysfunction of the
orthosympathetic system, which is the limb of the ANS gauged
by this test. This is consonant with findings in subjects with
dementia (AD): Giubilei at al. found a marked blunting of the
response to head-up tilt [18] and de Vilhena et al., although not
directly evaluating variations in HRV indices, provide data that
show unchanged LFn and HFn in the transition from the supine to
the active standing position [21]. In response to paced breathing
the physiological increase in HFn and the physiological decrease in
LFn and LF/HF were not significantly different between the two
groups, suggesting that in MCI subjects there is no dysfunction of
the parasympathetic system, which is the limb of the ANS
explored by this test. Since there are no studies employing paced
breathing protocols and HRV analysis not only in MCI but also in
dementia, these results are more difficult to place into context, but
impaired clinical parasympathetic tests like the HR response to
deep breathing [13] have been described in subjects with AD as
well as with other forms of dementia [16]. Thus, it can be
presumed that parasympathetic dysfunction sets in at a more
advanced stage of cognitive decline. However, it must also be
stressed that there is inconsistency in the literature as to the HR
response of AD subjects to deep breathing, maybe due to
methodological discrepancies across different studies, with reports
of no differences relative to controls [12,15,16]. Therefore, an
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Table 1. Baseline characteristics of the study subjects
Variable NC (n=40) MCI (n=40) p
Age (years) 77.8 (4.5) 79.4 (5.3) 0.145 b
Gender, female 33 (82.5) 27 (67.5) 0.121 d
Education (years) 11.4 (4.4) 10.5 (4.4) 0.279 c
BMI (kg/m2) 24.1 (3.0) 24.6 (3.2) 0.431 b
Hypertension 21 (52.5) 24 (60.0) 0.499 d
SBP (mm Hg) 134.8 (19.2) 129.0 (17.4) 0.158 b
DBP (mm Hg) 75.2 (8.7) 73.6 (8.3) 0.404 b
Heart rate (beats/min) 65.2 (8.7) 69.6 (9.6) 0.035 b
Respiratory rate (cycles/min) 14.0 (2.4) 15.0 (2.8) 0.104 b
Smoking 2 (5.0) 1 (2.5) 1.000 e
Alcohol (AU/day) 1.3 (1.6) 1.3 (1.5) 0.968 c
Coffee (cups/day) 1.5 (1.0) 1.3 (1.1) 0.317 c
Physical activity (MET-hours/week) 68.4 (39.3) 57.6 (39.8) 0.144 c
Family history of premature CAD 7 (17.5) 7 (17.5) 1.000 d
Glucose (mg/dl) 87.7 (9.8) 91.5 (10.0) 0.107 b
Total cholesterol (mg/dl) 222.9 (37.8) 227.0 (33.9) 0.635 b
LDL cholesterol (mg/dl) 137.6 (33.0) 139.7 (28.0) 0.768 b
HDL cholesterol (mg/dl) 69.2 (20.5) 65.8 (18.2) 0.470 c
Triglycerides (mg/dl) 104.0 (32.4) 106.7 (36.4) 0.745 b
Target organ damage
LVH-echocardiography 16 (40.0) 20 (50.0) 0.369 d
Carotid atherosclerosis
Thickening (IMT .0.9 mm) 35 (87.5) 30 (75.0) 0.152 d
plaque/s 33 (82.5) 29 (72.5) 0.284 d
Number of medications 3.3 (1.7) 3.8 (2.2) 0.311 b
Antihypertensive medications
ACE-Is/ARBs 16 (40.0) 23 (57.5) 0.117 d
Diuretics 7 (17.5) 9 (22.5) 0.576 d
CCBs (peripherally-acting) 3 (7.5) 8 (20.0) 0.105 d
Psychotropic medications
SSRIs 9 (22.5) 13 (32.5) 0.317 d
Benzodiazepines a 8 (20.0) 7 (17.5) 0.775 d
BADL score 5.5 (0.5) 5.6 (0.6) 0.325 c
IADL score 7.4 (1.2) 6.7 (1.6) 0.006 c
MMSE score 28.6 (1.0) 26.8 (2.0) ,0.001 b
CIRS-s score 1.6 (0.2) 1.4 (0.2) 0.029 b
CIRS-m score 2.5 (1.3) 1.7 (1.1) 0.006 c
STPI-T score 19.5 (5.7) 19.6 (5.7) 0.843 c
GDS-s score 3.4 (3.1) 3.2 (2.8) 0.747 c
Continuous variables are expressed as mean (SD), categorical variables are expressed as n (%). Significant results are shown in bold typeface.




eFisher’s exact test. NC: normal cognition (controls); MCI: mild cognitive impairment; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure;
AU: alcohol units (1 AU= 10 g of alcohol); MET: metabolic equivalent (energy expenditure index, 1 MET = 1 kcalNkg21Nh21); CAD: coronary artery disease; LDL: low
density lipoprotein; HDL: high density lipoprotein; LVH: left ventricular hypertrophy; IMT: intima-media thickness; ACE-Is: angiotensin converting enzyme inhibitors;
ARBs: angiotensin II receptor blockers; CCBs: calcium-channel blockers; SSRIs: selective serotonin reuptake inhibitors; BADL: basic activities of daily living (score range 0–
6, higher scores indicate greater functional independence); IADL: instrumental activities of daily living (score range 0–8, higher scores indicate greater functional
independence); MMSE: mini mental state examination (score range 0–30, higher scores indicate better cognitive function); CIRS-s: cumulative illness rating scale severity
(score range 1–5, higher scores indicate greater comorbidity); CIRS-m: cumulative illness rating scale morbidity (score range 0–13, higher scores indicate more severe
comorbidity); STPI-T: state trait personality inventory- trait anxiety subscale (score range 10–40, higher scores indicate greater trait anxiety); GDS-s: geriatric depression
scale short form (score range 0–15, higher scores indicate greater depressive symptoms).
doi:10.1371/journal.pone.0096656.t001
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alternative hypothesis could be that there occurs no parasympa-
thetic dysfunction in either MCI or dementia.
Whatever the case, our findings suggest that in subjects with
MCI there is a preferential impairment of the orthosympathetic
limb of the ANS. The pathophysiological mechanism mediating
the association between MCI and such pattern of autonomic
dysfunction could be right insular damage. In fact the insula is a
key hub of the central autonomic network (CAN), a complex
network of central nervous system units that is implicated both in
cognitive functioning and in the regulation of ANS output via
projections on preganglionic parasympathetic and orthosympa-
thetic neurons of the dorsal motor nucleus of the vagus and the
intermediolateral cell columns of the spinal cord [109]. It is
acknowledged, based on histopathological and neuroimaging
studies, that the insulae are affected in the early preclinical stages
of dementia [110,111] and there is emerging evidence that the
right insula may be the most involved [112,113]. It is generally
accepted that the right insula is predominantly responsible for
orthosympathetic CV control, as testified by a body of functional
neuroimaging and cardiovascular data in healthy young volunteers
[114,115], as well as patients with epilepsy [116], with tinnitus
[117] and, despite some amount of controversy, with stroke [116].
In addition, it has more recently been shown that in non demented
older adults free of significant CV disease an absolute reduction in
right insular blood flow on functional magnetic resonance imaging
was significantly associated with a greater drop in SBP during a sit-
stand manoeuvre [113].
It can also be speculated that the pathophysiological substrate of
the attenuated orthosympathetic activation and parasympathetic
withdrawal in MCI subjects during active standing is a lesion of
the locus coeruleus (LC). Indeed the LC, another component of
the CAN, is among the first brain sites undergoing histopatholog-
ical changes in MCI [118] and is activated by BP reductions [119],
producing an increase in orthosympathetic and a decrease in
parasympathetic activity [120].
In subjects with MCI the SBP after 10 minutes of active
standing was lower than in controls, suggesting orthostatic BP
dyregulation. This corroborates results from previous scant
research in the area of BP regulation in MCI, indicating a
three-fold increase in the prevalence of OH in MCI compared to
cognitively normal subjects [51] and a higher prevalence of MCI
relative to normal cognition in subjects with abnormal nocturnal
BP profiles [50]. However, unlike Mehrabian et al. [39] we found
that the difference in the prevalence of OH in the two groups,
although in the expected direction (i.e. prevalence of OH about
1.8-fold higher in MCI), was not statistically significant. Such
discrepancy is very likely explained by the much smaller sample
size of our study coupled with the fact that OH is a binary yes/no
variable based on an arbitrary threshold definition and as such is
less sensitive in capturing differences between the groups than is a
continuous variable like standing SBP.
Orthostatic BP dysregulation could hold particular clinical
significance in elderly subjects in whom a shift of the cerebral
autoregulation curve towards higher BP values increases vulner-
ability to cerebral hypoperfusion [121]. Indeed it has been shown
that even in healthy elderly without OH there was a significant
decrease in cortical oxygenation during 10 minutes of active
standing when compared with young subjects with the same
postural BP change [122].
Table 2. Characteristics of the study subjects during the experimental session
Variable NC (n=40) MCI (n =40) p q d
SBP after 1 min standing (mm Hg) 134.7 (20.3) 127.2 (18.0) 0.088 a 0.157
DBP after 1 min standing (mm Hg) 82.1 (10.0) 78.1 (10.1) 0.080 a 0.156
Heart rate after 1 min standing (beats/min) 71.6 (11.0) 75.7 (11.3) 0.115 b 0.185
SBP after 3 min standing (mm Hg) 137.7 (18.9) 129.0 (16.7) 0.034 a 0.092
DBP after 3 min standing (mm Hg) 82.1 (10.4) 78.7 (8.5) 0.111 a 0.185
Heart rate after 3 min standing (beats/min) 68.8 (9.6) 73.3 (10.0) 0.047 a 0.103
SBP after 5 min standing (mm Hg) 134.8 (20.5) 128.1 (16.6) 0.115 a 0.185
DBP after 5 min standing (mm Hg) 81.7 (10.1) 78.6 (9.0) 0.150 a 0.194
Heart rate after 5 min standing (beats/min) 69.5 (11.3) 73.6 (9.8) 0.085 a 0.157
SBP after 10 min standing (mm Hg) 135.2 (21.4) 124.4 (16.0) 0.012 a 0.047
DBP after 10 min standing (mm Hg) 82.2 (11.2) 78.7 (8.8) 0.122 a 0.185
Heart rate after 10 min standing (beats/min) 70.9 (10.6) 74.5 (9.9) 0.119 b 0.185
Orthostatic hypotension 4 (10) 7 (17.5) 0.330 c 0.385
SBP end of paced breathing (mm Hg) 146.0 (19.9) 139.1 (20.5) 0.132 a 0.185
DBP end of paced breathing (mm Hg) 84.3 (9.8) 81.6 (10.6) 0.249 a 0.301
Heart rate end of paced breathing (beats/min) 57.9 (6.9) 63.7 (8.1) 0.001 a 0.018
Respiratory rate standing (cycles/min) 14.9 (2.7) 15.9 (3.1) 0.161 a 0.201
D Respiratory rate (cycles/min) 0.9 (1.9) 0.9 (1.6) 0.496 b 0.526
VAS stress score standing 33.7 (22.4) 20.4 (20.4) 0.007 b 0.041
VAS stress score paced breathing 42.2 (23.6) 28.5 (23.3) 0.019 b 0.055
Continuous variables are expressed as mean (SD), categorical variables are expressed as n (%). Significant results are shown in bold typeface. a Student’s t-test; b Mann-
Whitney’s U-test; c Chi-squared test; d correction for multiple testing by means of the Benjamini-Hochberg procedure with a 5% False Discovery Rate (FDR). NC: normal
cognition (controls); MCI: mild cognitive impairment; SBP: systolic blood pressure; DBP: diastolic blood pressure; D respiratory rate: respiratory rate standing- respiratory
rate baseline; VAS: visual analogue scale (score range 0–100, higher scores indicate greater stress).
doi:10.1371/journal.pone.0096656.t002
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It could therefore be conjectured that MCI leads to dysauto-
nomia through a disruption in central autonomic control,
wherever the site of the lesion within the CAN, and that a vicious
circle might thereby ensue by which dysautonomia-associated
orthostatic SBP dysregulation may result in cerebral hypoperfu-
sion and brain damage that contribute to the progression of
cognitive decline towards overt dementia. This latter possibility is
of considerable clinical interest in the quest for predictors of
evolution to dementia and deserves some discussion. It is true that
in the literature there is a lack of direct evidence that
dysautonomia causes cognitive decline since the studies investi-
gating HRV in dementia or MCI [16–22,54] are cross-sectional
and the prospective analyses from the study by Britton et al. [23]
reveal only a weak association between HRV at baseline and
changes in cognition at follow-up. However, Britton et al. focus on
a population at lower risk of cognitive decline (middle-aged adults
not selected for cognitive impairment) and do not carry out
detailed neuropsychological testing. Also, the literature provides
several distinct pieces of evidence that fit in well with the
hypothesis that dysautonomia may accelerate cognitive decline via
orthostatic BP dysregulation and WMLs. In a sample of geriatric
patients a SBP ,130 mm Hg was demonstrated to be an
independent predictor of WMLs [42]. In MCI subjects a greater
WML burden increased the likelihood and rate of cognitive
decline [123] as well as the risk of conversion to dementia [124].
To close the circle, large prospective population-based studies in
older adults have shown that a baseline SBP ,130 mm Hg [125]
or ,110 mm Hg [126] was associated with worse cognitive
performance at follow-up and that an increase in SBP decreased
the risk of developing dementia in people on antihypertensive
Table 3. Power spectral analysis of heart rate variability in the two groups of subjects
Variable NC (n=40) MCI (n=40) p q b adjusted p c
LFn (n.u)
baseline 48.7 (18.1) 49.2 (20.0) 0.910 0.910
standing 65.8 (17.0) 52.7 (20.0) 0.002 0.018 0.009
paced breathing 38.1 (18.0) 49.1 (18.7) 0.009 0.041 0.006
D standing 17.1 (16.8) 3.6 (25.7) 0.007 0.041 0.012
D paced breathing 210.6 (20.7) 20.1 (23.1) 0.036 0.092
HFn (n.u) a
baseline 30.9 (15.7) 27.5 (13.1) 0.430 0.470
standing 18.5 (10.3) 26.2 (14.3) 0.015 0.049 0.018
paced breathing 47.7 (18.5) 38.6 (17.3) 0.035 0.092
D standing 212.5 (14.2) 21.4 (13.4) 0.001 0.018 0.003
D paced breathing 16.7 (20.0) 11.0 (17.1) 0.374 0.422
LF/HF a
baseline 2.4 (2.2) 2.7 (2.7) 0.605 0.623
standing 5.2 (3.8) 3.4 (3.3) 0.003 0.021 0.006
paced breathing 1.2 (1.5) 1.8 (1.5) 0.014 0.049 0.039
D standing 2.8 (2.6) 0.7 (3.0) ,0.001 0.004 ,0.001
D paced breathing 21.2 (2.0) 20.9 (2.8) 0.075 0.154
HRV indices, expressed as mean (SD), in baseline conditions and during and in response to (D) provocative tests (active standing, paced breathing). Significant results
are shown in bold typeface.
astatistical analyses performed on log 10 - transformed variable;
bcorrection for multiple testing by means of the Benjamini-Hochberg procedure with a 5% False Discovery Rate (FDR);
cadjustment for potential confounders by means of multiple linear regression (see text for details). NC: normal cognition (controls); MCI: mild cognitive impairment; n.u.:
normalized units; LFn: low frequency power (normalized); HFn: high frequency power (normalized); LF/HF: LF to HF ratio; D standing: standing HRV index - baseline HRV
index; D paced breathing: paced breathing HRV index - baseline HRV index.
doi:10.1371/journal.pone.0096656.t003
Figure 3. Systolic blood pressure after 10 minutes of active
standing in the two groups of subjects. Bars represent the mean
and error bars represent one standard deviation (SD). a adjustment for
potential confounders by means of multiple linear regression (see text
for details). SBP: systolic blood pressure; NC: normal cognition
(controls); MCI: mild cognitive impairment.
doi:10.1371/journal.pone.0096656.g003
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medication (per 10 mm Hg: relative risk = 0.93) [127]. Further-
more, within a group of MCI subjects, reduced HRV indices have
been reported to positively correlate with WML severity [54].
Finally, cerebral hypoperfusion [128] and right insular atrophy
[129] were observed on neuroimaging in converting versus stable
MCI subjects.
Also, it can be supposed that in MCI subjects dysautonomia-
associated orthostatic SBP dysregulation could play a role in the
increased risk of falls [47,48] and subsequent morbidity and
mortality, through haemodynamic changes [41] which may be
superimposed on a background of gait and balance disturbances
due to WMLs [44] possibly induced by the lower SBP [42].
The ongoing follow-up of our study population will be
important to better clarify the clinical relevance of autonomic
dysfunction (and orthostatic BP dysregulation) in terms of the
likelihood and rate of progression to dementia, the incidence of
falls and the risk of mortality, be it fall-related or more generally
associated with the disruption of the homeostasis-maintaining
function of the ANS [11]. Along this avenue of research, which
needs the contribution of further and larger studies, autonomic
dysfunction could prove to be a predictor of adverse health
outcomes in MCI subjects and autonomic assessment could then
be used to help identify high-risk individuals to whom appropriate
interventions should be targeted.
Among the strengths of our study- including fully controlled
experimental conditions, the use of provocative tests to differen-
tially challenge the two branches of the ANS and performance of
PSA according to rigorous methodological standards- was the fact
that we collected information on a number of potential
confounders and adjusted for them when appropriate. These
included drug history, comorbidity and protocol-induced emo-
tional stress. With regard to the latter two items it is worth
mentioning that both CIRS and VAS-stress scores were lower (or
marginally lower) in MCI subjects than in controls. The lesser
comorbidity found in subjects with MCI could stem from the
nature of our sample, consisting of older adults referred to a
Geriatric Unit for specialist care by their GPs. In fact it may be
assumed that referral for suspected cognitive disturbances is a
routine practice while geriatric evaluation for other clinical
conditions is deemed necessary only when they are multiple or
particularly severe. The lower levels of stress reported by MCI
subjects could be attributed to different reasons. Difficulty in using
the VAS scale does not appear plausible because this simple scale
has been successfully employed for the rating of quality of life in
individuals with mild to moderate AD [130]. A greater tendency to
understate stress is also unlikely since the two groups did not differ
in scores on the short form of the Marlowe-Crowne scale [131]
that investigates socially desirable responding (20.162.8 MCI vs
19.762.6 NC, p = 0.539, data not shown). It therefore appears
that patients with MCI actually experience less stress. Although we
are not aware of studies comparing individuals with MCI and NC
on their response to specific stressors, it is known that apathy is one
of the most frequent behavioural symptoms in MCI [132] and
emotional blunting might reduce the appraisal of stress. Also,
subjects with MCI often display anosognosia for cognitive deficits
[133] and in a sample of older adults spanning the cognitive
spectrum it has been demostrated that anosognosia for dementia
positively correlated with anosognosia for perceived stress [134].
There are some limitations to our study. Its cross-sectional
design precludes conclusions on the direction of causality in the
association between MCI and autonomic dysfunction, which can
only be elucidated by longitudinal studies. As previously
mentioned, the follow-up of the study population will also be
particularly important to better clarify the prognostic significance
of autonomic dysfunction (and orthostatic BP dysregulation) in
terms of adverse health outcomes, and is currently under way.
Medication use by the study participants is a critical issue which
requires discussion. Since this is an exploratory study of a clinical
population – and specifically of older adults, which implies a
particularly high rate of comorbidity-related polypharmacy – the
inclusion of medication users is consonant with the nature of the
study. In fact, given that many drugs have a presumed impact on
the ANS, the approach of excluding all medications that may
affect HRV (e.g. [18,21,22], would have yielded a sample of
subjects not representative of the underlying population. On the
other hand, including all medications (e.g. [36,54]) would have
resulted in an undue pharmacological influence on HRV. Thus,
we chose to exclude some medications while accepting others
(please see Methods for the exclusion/inclusion criteria), in line
with previous studies on HRV involving subjects likely to be on
polypharmacy because of general age-related comorbidity (e.g.
[19,135–139]) or specific clinical conditions like heart disease (e.g.
[137,140,141]). Although the allowed medications (ACE-Is/ARBs,
diuretics, peripherally-acting CCBs, SSRIs, benzodiazepines) can
be considered a source of confounding, and although a subgroup
analysis excluding them is not feasible on account of the marked
decrease in sample size (n = 12 NC vs n = 10 MCI) and hence in
statistical power, it should be remarked that there was no
significant difference between the two groups in the prevalence
of use of each of these classes of medications, enabling meaningful
comparisons to be made. Moreover, the statistical analyses were
also corrected for medication use. Therefore it seems reasonable to
suppose that medication use is not inappropriately interfering with
our findings. This line of reasoning holds true for all the
medications mentioned but could be of even more relevance in
the case of psychotropic medications with a potential to affect both
HRV and cognition. Indeed, as far as benzodiazepines were
concerned, since they can be taken not only regularly but also as
needed, in order to ensure that benzodiazepine use was
predictable, thereby enabling comparison between groups, only
regular users were allowed while intermittent users were asked to
refrain from benzodiazepine consumption prior to testing (please
see Methods and Table 1).
As to the medication selection criteria, even if we acknowledge
there may be some degree of arbitrariness in our choice of
exclusion/inclusion criteria it is worth noting that we strived to
make it as objective as possible by grounding it in the literature. To
this end we decided to exclude medications which have been
consistently and significantly shown to affect HRV: beta-blockers
[8,142], alpha-blockers [143,144]), centrally-acting CCBs [145–
150]), class I and class III antiarrhytmic drugs [8,142], digoxin
[142], tryciclic antidepressants [57,151,152], antipsychotics [153–
155], SNRIs [56,152] and cholinesterase inhibitors [18,156].
Atypical antidepressants (e.g. mirtazapine, trazodone) were also
excluded because very few studies exist on their effect on HRV
and results are conflicting [57,151,157–159]. We instead allowed
medications whose influence on HRV has consistently been found
to be nil to limited – selective serotonin reuptake inhibitors (SSRIs)
[56,57,151,152] and diuretics [160,161] - or remains controversial
despite a rather large body of research- peripherally-acting CCBs
[148,149,161–164] and benzodiazepines [154,165–169].
Although benzodiazepines have the potential to affect the
activity of the central ANS, since it contains GABAergic neurons
[170], their impact on HRV can be considered at least
controversial. In fact the oral benzodiazepines, used for the
treatment of insomnia and anxiety in community-dwelling
subjects, unlike the intravenous ones [171,172] have mostly been
reported to have no effect on HRV [165,167,169], with some
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exception [166,168]. Moreover, a recent and larger study in
patients with schizophrenia [154], making no distinction between
routes of administration, demonstrated that daily benzodiazepine
dose was not associated with frequency-domain measures of HRV.
Finally, ACE-inhibitors (ACE-Is)/angiotensin II receptor block-
ers (ARBs) were also permitted. Despite the fact that the literature
is largely in favour of an effect of these medications on HRV
[142,163,173,174], with only some occasional evidence of no
effect [160–162], we still believed it would be reasonable to allow
them based on the notion that hypertension has a very high
prevalence in the elderly [175] and that they are the most
commonly prescribed antihypertensives [176], meaning that their
exclusion would greatly detract from the generalizability of our
findings.
Since the exclusion/inclusion criteria include several cardioac-
tive medications often employed as antihypertensives, their
application could also be having an impact on the hypertensive
subjects in the study population. With regard to the exclusion
criteria, excluding some antihypertensive medications could mean
selecting untreated (i.e. unrecognized) hypertensives as well as
hypertensives treated with a lesser number of medications-
uncontrolled and potentially uncontrolled hypertensives respec-
tively. Although such possibility cannot be definitely ruled out
because the study, with a single baseline BP measurement and no
24-hour ambulatory BP monitoring [177], was not designed to
diagnose hypertension or to assess its pharmacological control, two
points are worth making. First, if there actually are unrecognized
hypertensives we would not expect them to be differently
distributed within the two groups. Moreover, the 56% prevalence
of hypertension found in the study population is very close to the
66% reported when investigating an ambulatory elderly popula-
tion [178], considering that in our case some of the hypertensives
were lost due to exclusion criteria; this seems to suggests that
unrecognized hypertension is not a major problem in our study,
consistently with the fact that it enrolled older adults accessing
secondary care who are likely to have been screened for high BP
by their GPs. Second, hypertensives treated with a lesser number
of medications are not necessarily uncontrolled hypertensives; on
the contrary they may be subjects whose hypertension is more
amenable to therapy. With regard to the inclusion criteria,
allowing medications with either consistent (e.g. ACE-Is/ARBs) or
controversial (e.g. peripherally-acting CCBs) evidence of an effect
on HRV could also be a methodological concern. In fact, while it
is recognized that untreated hypertension is characterized by
dysautonomia [9] the autonomic profile of treated hypertensives
appears to depend on the medication used, beyond its BP-lowering
effect (e.g. [148–150,160,163,174]). Therefore, it could be
objected that, although all subjects recorded as hypertensives in
our study were known hypertensives on stable treatment and there
was no significant difference in the prevalence of hypertension
between the two groups, their autonomic status could differ.
However, this does not seem to be the case because, as already
discussed, medication use was similar in MCI and NC subjects and
it was also adjusted for in statistical analyses.
As to the question of how representative the study sample is of a
clinical and/or community-dwelling elderly population, some
issues should be borne in mind. The use of exclusion criteria
inevitably implies that the subjects enrolled cannot be fully
representative of the population considered for inclusion. In fact,
even though we limited exclusion criteria as much as possible, the
80 subjects included differed from the overall 475 in terms of
several characteristics. On account of the exclusion of a number of
medications and clinical conditions (including dementia), they
showed less comorbidity and polypharmacy as well as better
functional and cognitive status, as expected. The borderline higher
education could be a consequence of the exclusion of individuals
suffering from dementia since there is a recognized inverse
relationship between education and risk of dementia [179]. The
female predominance might stem from the higher prevalence
among males of excluded CV diseases such as CAD and HF [180].
The lower prevalence of diuretic use can speculatively be ascribed
to the fact that diuretics are mainstay of HF treatment in the
elderly [181] and HF was excluded. Furthermore, the generaliz-
ability of our findings to the older community-dwelling population
at large may be limited by the nature of the recruited population
(i.e. outpatients attending a Geriatric Unit) which may have biased
the sample towards subjects with poorer cognitive status and worse
health. However, with regard to cognitive status, although some
degree of bias cannot be excluded, it is important to note that our
Geriatric Unit does not exclusively address cognitive disturbances
but a wide variety of age-related health problems and that in our
experimental design subjects were invited to undergo on-site
neuropsychological testing independently of cognitive functioning
and responded with a very high participation rate (113 out of 117,
i.e. about 97%, agreed to testing). Also, as far as overall health was
concerned, selection bias probably operated in two opposite
directions, with outpatients referred to the Geriatric Unit having
worse health but then being selected for better health based on the
exclusion criteria.
The sample size was relatively small and, although in line with
or indeed larger than that of other HRV studies on subjects with
MCI and AD [18,19,21,54] it did not allow us to investigate
autonomic function across different MCI subtypes [1].
The diagnosis of MCI was based on current consensus criteria:
objective cognitive impairment documented by neuropsycholog-
ical testing, essentially preserved functional independence and
absence of dementia. Consistently with most other studies [75] we
did not take into account the subjective and longitudinal criteria.
The first is defined by a cognitive concern reported by the patient
and/or an informant and whether it should be adopted is a matter
of debate [75,182]. In fact patients with MCI often lack self-
awareness [75,133,183] while subjects who complain about
cognition may be depressed or anxious [75,184]. Although
informant reports have generally been shown to correlate well
with objective cognitive performance in MCI, their clinical use is
hampered by the lack of validated rating instruments and the
potential bias stemming from the informant’s personal character-
istics [183] including the fact that MCI caregivers are mostly
spouses [185] and thus older adults who may themselves be
cognitively impaired. The second criterion corresponds to an
objective cognitive decline over time and its omission is due to the
cross-sectional design of the study. Prospective neuropsychological
testing could probably have improved the accuracy of MCI
classification by providing evidence of intraindividual change in
cognition. However, recent guidelines recognize that an MCI
diagnosis will likely need to be given without the benefit of serial
cognitive assessments [60]. Also, it should be noted that whereas
declining cognition is suggestive of MCI, the reverse may not be
true- i.e. a significant proportion of MCI patients actually remain
stable at follow-up [186].
Tidal volume was not controlled or measured, but subjects were
simply asked to breathe normally during baseline conditions and
active standing and at a ‘‘comfortable’’ tidal volume during paced
breathing. Although this is a potential methodological issue, it is
bound to have little practical meaning since there is no reason to
assume that tidal volume was different in the two groups and it is
acknowledged that, compared to respiratory rate (which was
indeed taken into account) tidal volume is a much less potent
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determinant of HF [92] with negligible effects within the
physiological breathing range [93]. Also, controlling or measuring
tidal volume would have increased the stress and complexity of the
protocol. On such grounds, in our study, like in the vast majority
of HRV publications [93], tidal volume was not considered.
Lastly, it can also be argued that the presence of subjects with
bradycardia may be affecting our findings by reducing the number
of beats available for analysis. However, ectopics were edited by
linear interpolation rather than simple deletion (please see HRV
analysis), implying no loss of data from the 5-minute recordings,
and it has been reported that PSA on data segments 3 to 5 minutes
long provides reliable results, regardless of whether the subject has
a high or low basal HR [187]. In addition, corrections for HR
were performed in the statistical analyses.
Conclusions
To the best of our knowledge this is the first study, based on a
reliable and comprehensive assessment of autonomic function by
means of PSA of HRV in different conditions, to demonstrate
autonomic dysfunction in subjects with MCI compared to
cognitively normal controls, after adjustment for potential
confounders. The autonomic dysfunction was not detectable in
baseline conditions but only during and in response to provocative
tests, was consistent with orthosympathetic impairment, and was
associated with orthostatic BP dysregulation. The underlying
physiopathological mechanism could be disruption of central
autonomic control due to right insular or locus coeruleus damage.
The potential clinical relevance of autonomic dysfunction in MCI
is manifold, as there is convincing evidence it may play a role in
progression to dementia, in the increased risk of mortality and
falls, and it may be affected by pharmacological treatments.
Longitudinal studies will be required to assess the direction of
causality and to better clarify the prognostic significance of the
autonomic dysfunction in terms of adverse health outcomes.
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